Insmed Details ATS 2026 Respiratory Portfolio

Key Takeaways

• Insmed will present six abstracts at ATS 2026.
• Abstract topics include ENCORE data, brensocatib and bronchiectasis, treprostinil palmitil inhalation powder pharmacokinetics, bronchiectasis burden, and real-world PH-ILD data.

Insmed will present six abstracts at the American Thoracic Society International Conference 2026, scheduled for May 17–20 in Orlando, Florida. The lineup is led by a late-breaking Phase 3b ENCORE presentation on ARIKAYCE.

The ENCORE study is evaluating ARIKAYCE plus once-daily multidrug therapy versus placebo plus once-daily multidrug therapy in newly diagnosed MAC lung disease.

Beyond ENCORE, the listed ATS program includes a post hoc ASPEN analysis of brensocatib, a treprostinil palmitil inhalation powder pharmacokinetic analysis, a patient and caregiver survey on bronchiectasis burden, a real-world PH-ILD claims-database study, and an exposure-response brensocatib analysis.